Medicine has always aspired to treat the individual. Yet for most of its history, it has treated the average. A drug approved for millions is calibrated to a statistical middle ground — effective for many, suboptimal for some, harmful for a few. That era is drawing to a close. Personalized gene editing is no longer…
Month: September 2026
Space as a Business Frontier: Next Decade for Investors
For decades, space was the domain of governments — a symbol of national prestige, scientific ambition, and geopolitical competition. Today, it is becoming something else entirely: a rapidly emerging commercial market. The shift is not incremental. It is structural. Launch costs are falling. Private capital is flowing. Entire industries are being rebuilt with space infrastructure…

